(Q43118124)

14 November 2017

title

Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation (English)

1 reference

14 November 2017

1 reference

F Viola

1

1 reference

14 November 2017

C Mapelli

2

1 reference

14 November 2017

E Villani

3

1 reference

14 November 2017

F Tresca Carducci

4

1 reference

14 November 2017

D Vezzola

5

1 reference

14 November 2017

R Ratiglia

6

1 reference

14 November 2017

publication date

26 March 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

24

1 reference

14 November 2017

issue

8

1 reference

14 November 2017

page(s)

1344-1351

1 reference

Retinal angiomatous proliferation: natural history and progression of visual loss

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Retinal angiomatous proliferation in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Focal laser ablation of retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Combining surgical ablation of retinal inflow and outflow vessels with photodynamic therapy for retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Recurrent retinal angiomatous proliferation after surgical ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

7 January 2021

Diabetic Macular Edema: Correlation between Microperimetry and Optical Coherence Tomography Findings

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

7 January 2021

Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

7 January 2021

Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

7 January 2021

Current treatment options for retinal angiomatous proliferans (RAP).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.33

7 January 2021

Identifiers

DOI

10.1038/EYE.2010.33

1 reference

Dimensions Publication ID

14 November 2017

1000653098

0 references

1 reference